Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
id: 580, Created by Stan Vick, Scout

Sorrento (SRNE) Misconduct Case

  • Sorrento (SRNE) commenced Chapter 11 proceedings.
  • SRNE's stock dropped by 72.6% and lost $374M of market cap, seriously damaging Investors.
  • Investors suspect the Company & its Leaders of breach of fiduciary duties.
On February 13, 2023, Sorrento Therapeutics (NASDAQ: SRNE) released an 8-K filing with the SEC stating that the Company, and its wholly-owned subsidiary Scintilla Pharmaceuticals, have voluntarily commenced a Chapter 11 bankruptcy proceeding in the U.S. Bankruptcy Court for the Southern District of Texas.

  • Investing community links SRNE's Chapter 11 filing to the Company's pending litigation about the 2015 JV known as NANTibody with billionaire biotech investor Dr. Patrick Soon-Shiong and the related entities.
  • In December 2022, an arbitrator issued an award granting contractual damages and pre-award interest in the amount of $156.8M to Soon-Shiong's company NantCell, a subsidiary of ImmunityBio. Additionally, the court awarded NANTibody $16.7M.
  • On February 7, 2023, the court confirmed the judgment that put Sorrento (SRNE) and the affiliates at risk of asset seizure but the bankruptcy filing could postpone any potential asset seizures.
Even though the radical step of the Company could have been dictated by the assets protection and the operational activities preservation, nevertheless, these actions became a surprise for Investors and the market and led to significant losses for shareholders, which gives the latter reason to suspect that the Company and its Leaders have breached their fiduciary duties.
Alleged Offence
Breach of Fiduciary duty
Suspected Party
Investment Bank
Service Provider
Security Type
Trade Direction
Shock Event Date
13 February 2023
Collecting participants…
Created by Stan Vick, Scout

Case history

Stan Vick
28 August 2023
$SRNE Case News:
  • Sorrento Therapeutics has secured Texas court approval for the $105 million sale of its stake in subsidiary Scilex Holding Co. This decision comes after a bankruptcy judge rejected the request of other Scilex shareholders to reopen the auction for the assets in order to place their own bid.
Stan Vick
13 September 2023
$SRNEQ Case News:
Sorrento Therapeutics received a Texas court's approval for subsidiary Scilex Holding to buy its own stock back from $SRNEQ for $110 million after the original buyer said closing conditions weren't met for its court-approved acquisition.

Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates t...

    Biotechnology & Medical Research
    4955 Directors Place, San Diego, CA, United States, 92121